JonesResearch analyst Debanjana Chatterjee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $40 from $41 and keeps a Buy rating on the shares post the Q3 report. The firm increased its projections for the company’s R&D spend to support three Phase 3 trials in coming years.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics reports Q3 EPS ($1.34), consensus ($1.39)
- Intellia Therapeutics Inc (NTLA) Q3 Earnings Cheat Sheet
- Intellia Therapeutics Advances with Promising Phase 2 Results
- Intellia Therapeutics price target lowered to $19 from $25 at Citi
- Intellia Therapeutics price target lowered to $65 from $80 at BofA